Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
It is not well understood why diabetic individuals are more prone to develop severe COVID-19. To this, we here established a human kidney organoid model promoting early hallmarks of diabetic kidney disease development. Upon SARS-CoV-2 infection, diabetic-like kidney organoids exhibited higher viral loads compared with their control counterparts. Genetic deletion of the angiotensin-converting enzyme 2 (ACE2) in kidney organoids under control or diabetic-like conditions prevented viral detection. Moreover, cells isolated from kidney biopsies from diabetic patients exhibited altered mitochondrial respiration and enhanced glycolysis, resulting in higher SARS-CoV-2 infections compared with non-diabetic cells. Conversely, the exposure of patient cells to dichloroacetate (DCA), an inhibitor of aerobic glycolysis, resulted in reduced SARS-CoV-2 infections. Our results provide insights into the identification of diabetic-induced metabolic programming in the kidney as a critical event increasing SARS-CoV-2 infection susceptibility, opening the door to the identification of new interventions in COVID-19 pathogenesis targeting energy metabolism.
Proyecto:
European Commission 640525
,
European Commission 101002478
,
European Commission 874827
,
Agencia Estatal de Investigación PID2020-119929RB-I00
,
Ministerio de Economía y Competitividad RYC-2014-16751
,
Agencia Estatal de Investigación PLEC2021-008127
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1306
,
Ministerio de Economía y Competitividad RD16/0011/0005
,
Ministerio de Economía y Competitividad RD16/0011/0027
,
Instituto de Salud Carlos III PTC20/00013
,
Instituto de Salud Carlos III PTC20/00130
,
Ministerio de Economía y Competitividad CB16/12/00489
,
Instituto de Salud Carlos III ACE2-ORG-COV20/00278
,
Instituto de Salud Carlos III RD21/0017/0018